Literature DB >> 3609667

Steatorrhea in patients with intrahepatic cholestasis of pregnancy.

H Reyes, M E Radrigan, M C Gonzalez, R Latorre, J Ribalta, N Segovia, C Alvarez, M Andresen, D Figueroa, B Lorca.   

Abstract

A prospective study was undertaken to evaluate fat malabsorption during intrahepatic cholestasis of pregnancy (ICP), a disease characterized by a mild cholestasis of short duration appearing in otherwise healthy young women. An abnormal fecal fat excretion (mean 15.8 g/24 h, range 6-31 g/24 h) was demonstrated in 10 of 12 patients with the icteric form of ICP and in 2 of 11 patients with pruritus gravidarum. The increased fecal fat excretion was generally asymptomatic, could be detected as early as 3 wk after the clinical onset of ICP, remained stable during the affected pregnancies, and returned to normal from 3 to 9 wk after delivery. Steatorrhea correlated with the severity of ICP, estimated by serum levels of bilirubin, total bile salts, and glutamic pyruvic transaminase. A significant fall in the maternal weight/height index was detected after the onset of ICP, being more intense in patients with steatorrhea than in those without it (to 92.6% +/- 3.0% of initial values versus 96.7% +/- 2.8%, respectively; p less than 0.05). A high risk of premature deliveries and fetal distress was demonstrated in these patients, also correlating with the severity of ICP. No direct relationship could be established between steatorrhea or maternal nutritional impairment and fetal prognosis.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3609667     DOI: 10.1016/0016-5085(87)90922-x

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  11 in total

Review 1.  Intrahepatic cholestasis of pregnancy-current achievements and unsolved problems.

Authors:  Jurate Kondrackiene; Limas Kupcinskas
Journal:  World J Gastroenterol       Date:  2008-10-14       Impact factor: 5.742

Review 2.  Intrahepatic cholestasis of pregnancy.

Authors:  Victoria Geenes; Catherine Williamson
Journal:  World J Gastroenterol       Date:  2009-05-07       Impact factor: 5.742

3.  Obstetric cholestasis.

Authors:  J B Weaver
Journal:  Br J Gen Pract       Date:  1995-02       Impact factor: 5.386

4.  Bile acid patterns in meconium are influenced by cholestasis of pregnancy and not altered by ursodeoxycholic acid treatment.

Authors:  C M Rodrigues; J J Marín; D Brites
Journal:  Gut       Date:  1999-09       Impact factor: 23.059

Review 5.  Approach to a patient with elevated serum alkaline phosphatase.

Authors:  Asma Siddique; Kris V Kowdley
Journal:  Clin Liver Dis       Date:  2012-04-06       Impact factor: 6.126

6.  The Multiple Facets of ABCB4 (MDR3) Deficiency.

Authors:  Shikha S Sundaram; Ronald J Sokol
Journal:  Curr Treat Options Gastroenterol       Date:  2007-12

7.  Fermentable fibers induce rapid macro- and micronutrient depletion in Toll-like receptor 5-deficient mice.

Authors:  Rachel M Golonka; Beng San Yeoh; Yaqi Li; Piu Saha; Ahmed A Abokor; Xi Cheng; Xia Xiao; Darshan Shimoga Chandrashekar; Sooryanarayana Varambally; David J Gonzalez; A Catharine Ross; Matam Vijay-Kumar
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2020-03-23       Impact factor: 4.052

8.  The prevalence and pregnancy outcomes of intrahepatic cholestasis of pregnancy: A retrospective clinical audit review.

Authors:  Fergus W Gardiner; Ruth McCuaig; Chris Arthur; Thomas Carins; Adam Morton; Josephine Laurie; Teresa Neeman; Boon Lim; Michael J Peek
Journal:  Obstet Med       Date:  2018-10-25

9.  Pilot study for a trial of ursodeoxycholic acid and/or early delivery for obstetric cholestasis.

Authors:  Vinita Gurung; Catherine Williamson; Lucy Chappell; Jenny Chambers; Annette Briley; Fiona Broughton Pipkin; Jim Thornton
Journal:  BMC Pregnancy Childbirth       Date:  2009-05-16       Impact factor: 3.007

Review 10.  Intrahepatic cholestasis of pregnancy.

Authors:  Thomas Pusl; Ulrich Beuers
Journal:  Orphanet J Rare Dis       Date:  2007-05-29       Impact factor: 4.123

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.